SRR8518205
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.350
- ESTROGEN_RESPONSE_LATE+0.350
- E2F_TARGETS+0.340
- ANGIOGENESIS+0.320
- HYPOXIA+0.310
- PANCREAS_BETA_CELLS+0.310
- KRAS_SIGNALING_DN+0.290
- MTORC1_SIGNALING+0.290
- UV_RESPONSE_UP+0.280
- TNFA_SIGNALING_VIA_NFKB+0.270
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.300
- MITOTIC_SPINDLE-0.260
- IL6_JAK_STAT3_SIGNALING-0.230
- PI3K_AKT_MTOR_SIGNALING-0.210
- INTERFERON_GAMMA_RESPONSE-0.180
- UV_RESPONSE_DN-0.180
- PROTEIN_SECRETION-0.140
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.120
- INTERFERON_ALPHA_RESPONSE-0.110
- BILE_ACID_METABOLISM-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013551 | — | cohortSQ1 | 0.785 |
| 2 | R111 | — | — | 0.763 |
| 3 | s0112232 | — | — | 0.744 |
| 4 | R308 | — | — | 0.725 |
| 5 | MNG1244 | — | — | 0.704 |
| 6 | SRR8943009 | — | — | 0.702 |
| 7 | R26 | — | — | 0.696 |
| 8 | C3L-02619 | — | cohortSQ1 | 0.690 |
| 9 | MBCproject_0253_T1_RNA | — | B | 0.688 |
| 10 | SRR35579835 | — | C | 0.677 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.350 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.350 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.340 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.290 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.280 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.180 | Idelalisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |